Genetic variance in CYP2C8 and increased risk of myocardial infarction

Pharmacogenetics and Genomics

Volumn 20, Issue 7, 2010, Pages 426-434

  Rodenburg, Eline M ^a   Visser, Loes E ^a,b   Danser, A H Jan ^a,b   Hofman, Albert ^a,d   Van Noord, Charlotte ^a,c   Witteman, Jacqueline C M ^a,d   Uitterlinden, André G ^a,d   Stricker, Bruno H Ch ^a,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Department of Hospital Pharmacy ^*

^c MEDICINES EVALUATION BOARD   (Netherlands)

^d Netherlands Consortium for Healthy Aging   (Netherlands)

Author keywords

arachidonic acid; CYP2C8; epoxyeicosatrienoic acid; myocardial infarction

Indexed keywords

CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; EPOXYICOSATRIENOIC ACID; SEX HORMONE; CYP2C8 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; ARTICLE; BLOOD VESSEL REACTIVITY; COHORT ANALYSIS; CYP2C8 GENE; FEMALE; FOLLOW UP; GENE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL; CHROMOSOME 10; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MYOCARDIAL INFARCTION; NETHERLANDS; PROPORTIONAL HAZARDS MODEL; SEXUAL DEVELOPMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; CHROMOSOMES, HUMAN, PAIR 10; CYTOCHROME P-450 CYP2C8; CYTOCHROME P-450 CYP2C9; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NETHERLANDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; SEX CHARACTERISTICS;

EID: 77953917248     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833a96d8     Document Type: Article

References (53)

1. Gray IC, Nobile C, Muresu R, Ford S, Spurr NK. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics 1995; 28:328-332.
2. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004; 429:464-468.
3. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52:349-355.
4. Fleming I. Cytochrome p450 and vascular homeostasis. Circ Res 2001; 89:753-762.
5. Miura H, Gutterman DD. Human coronary arteriolar dilation to arachidonic acid depends on cytochrome P-450 monooxygenase and Ca2 +-activated K+ channels. Circ Res 1998; 83:501-507.
6. Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 1999; 13:289-295.
7. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999; 401:493-497. (Pubitemid 29470209)
8. Delozier TC, Kissling GE, Coulter SJ, Dai D, Foley JF, Bradbury JA, et al. Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos 2007; 35:682-688.
9. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11:597-607.
10. Enayetallah AE, French RA, Thibodeau MS, Grant DF. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 2004; 52:447-454.
11. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82:131-185.
12. Michaelis UR, Fisslthaler B, Barbosa-Sicard E, Falck JR, Fleming I, Busse R. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci 2005; 118 (Pt 23):5489-5498.
13. Spiecker M, Liao JK. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 2005; 433:413-420.
14. Seubert JM, Zeldin DC, Nithipatikom K, Gross GJ. Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat 2007; 82:50-59.
15. Theken KN, Lee CR. Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk. Pharmacogenomics 2007; 8:1369-1383.
16. Fisslthaler B, Hinsch N, Chataigneau T, Popp R, Kiss L, Busse R, et al. Nifedipine increases cytochrome P4502C expression and endothelium-derived hyperpolarizing factor-mediated responses in coronary arteries. Hypertension 2000; 36:270-275.
17. Fleming I, Michaelis UR, Bredenkotter D, Fisslthaler B, Dehghani F, Brandes RP, et al. Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 2001; 88:44-51.
18. Lundblad MS, Stark K, Eliasson E, Oliw E, Rane A. Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes. Biochem Biophys Res Commun 2005; 327:1052-1057.
19. Quilley J, McGiff JC. Is EDHF an epoxyeicosatrienoic acid? Trends Pharmacol Sci 2000; 21:121-124.
20. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77:1-16.
21. Yasar U, Bennet AM, Eliasson E, Lundgren S, Wiman B, De Faire U, et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 2003; 13:715-720.
22. Visser LE, van Schaik RH, Jan Danser AH, Hofman A, Witteman JC, van Duijn CM, et al. The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Pharmacogenet Genomics 2007; 17:473-479.
23. Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U, et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 2002; 299:25-28.
24. Marciante KD, Totah RA, Heckbert SR, Smith NL, Lemaitre RN, Lumley T, et al. Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke. Pharmacogenet Genomics 2008; 18:535-543. (Pubitemid 351769921)
25. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet Genomics 2007; 17:349-358. (Pubitemid 46608542)
26. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991; 7:403-422.
27. Hofman A, Breteler MM, van Duijn CM, Krestin GP, Pols HA, Stricker BH, et al. The Rotterdam Study: objectives and design update. Eur J Epidemiol 2007; 22:819-829.
28. Hofman A, Breteler MM, van Duijn CM, Janssen HL, Krestin GP, Kuipers EJ, et al. The Rotterdam Study: 2010 objectives and design update. Eur J Epidemiol 2009; 24:553-572.
29. De Bruyne MC, Mosterd A, Hoes AW, Kors JA, Kruijssen DA, van Bemmel JH, et al. Prevalence, determinants, and misclassification of myocardial infarction in the elderly. Epidemiology 1997; 8:495-500.
30. World Health Organization. International statistical classification of diseases and health related problems, 10th revision. Geneva: World Health Organization; 1992.
31. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (Oxford, England) 2005; 21:263-265.
32. Liu MY, Hattori Y, Fukao M, Sato A, Sakuma I, Kanno M. Alterations in EDHF-mediated hyperpolarization and relaxation in mesenteric arteries of female rats in long-term deficiency of oestrogen and during oestrus cycle. Br J Pharmacol 2001; 132:1035-1046.
33. Villar IC, Hobbs AJ, Ahluwalia A. Sex differences in vascular function: implication of endothelium-derived hyperpolarizing factor. J Endocrinol 2008; 197:447-462.
34. Sakuma I, Liu MY, Sato A, Hayashi T, Iguchi A, Kitabatake A, et al. Endothelium-dependent hyperpolarization and relaxation in mesenteric arteries of middle-aged rats: influence of oestrogen. Br J Pharmacol 2002; 135:48-54.
35. Luksha L, Agewall S, Kublickiene K. Endothelium-derived hyperpolarizing factor in vascular physiology and cardiovascular disease. Atherosclerosis 2009; 202:330-344.
36. Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A. Calculating measures of biological interaction. Eur J Epidemiol 2005; 20:575-579.
37. Rothman K. Epidemiology. An introduction. New York: Oxford University Press; 2002.
38. Li R, Chambless L. Test for additive interaction in proportional hazards models. Ann of Epidemiol 2007; 17:227-236.
39. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology 1992; 3:452-456.
40. Sarasquete ME, Garcia-Sanz R, Marin L, Alcoceba M, Chillon MC, Balanzategui A, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 2008; 112:2709-2712.
41. Conne B, Stutz A, Vassalli JD. The 3 untranslated region of messenger RNA: a molecular 'hotspot' for pathology? Nat Med 2000; 6:637-641.
42. Grzybowska EA, Wilczynska A, Siedlecki JA. Regulatory functions of 3UTRs. Biochem Biophys Res Commun 2001; 288:291-295.
43. Mignone F, Gissi C, Liuni S, Pesole G. Untranslated regions of mRNAs. Genome Biol 2002; 3:1-10. REVIEWS0004.
44. Chen JM, Ferec C, Cooper DN. A systematic analysis of disease-associated variants in the 3 regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3 UTR variants. Hum Genet 2006; 120:301-333.
45. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 2008; 79:581-588.
46. Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha V, Lindblad-Toh K, et al. Systematic discovery of regulatory motifs in human promoters and 3 UTRs by comparison of several mammals. Nature 2005; 434:338-345.
47. Granville DJ, Tashakkor B, Takeuchi C, Gustafsson AB, Huang C, Sayen MR, et al. Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc Natl Acad Sci USA 2004; 101:1321-1326.
48. Hunter AL, Bai N, Laher I, Granville DJ. Cytochrome p450 2C inhibition reduces post-ischemic vascular dysfunction. Vasc Pharmacol 2005; 43:213-219.
49. Fichtlscherer S, Dimmeler S, Breuer S, Busse R, Zeiher AM, Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation 2004; 109:178-183.
50. Chehal MK, Granville DJ. Cytochrome p450 2C (CYP2C) in ischemic heart injury and vascular dysfunction. Can J Physiol Pharmacol 2006; 84:15-20.
51. Funk M, Endler G, Freitag R, Wojta J, Huber K, Mannhalter C, et al. CYP2C9*2 and CYP2C9*3 alleles confer a lower risk for myocardial infarction. Clin Chem 2004; 50:2395-2398.
52. Batenburg WW, Tom B, Schuijt MP, Danser AH. Angiotensin II type 2 receptor-mediated vasodilation. Focus on bradykinin, NO and endothelium-derived hyperpolarizing factor(s). Vasc Pharmacol 2005; 42:109-118.
53. Scotland RS, Madhani M, Chauhan S, Moncada S, Andresen J, Nilsson H, et al. Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation 2005; 111:796-803.